Drug Profile
Bepirovirsen - GSK
Alternative Names: 3228836; Bepirovirsen sodium; GSK'836; GSK-4388067; GSK-4388067A; GSK3228836; GSK3228836A; GSK3228836B; IONIS-HBVRx; ISIS 505358; ISIS-GSK3Rx; ISIS-HBVRxLatest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer GSK; Ionis Pharmaceuticals
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; RNA interference; Toll-like receptor 8 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hepatitis B
Most Recent Events
- 12 Feb 2024 Bepirovirsen receives Fast Track designation for Hepatitis B [SC,Injection] in USA
- 10 Nov 2023 Efficacy and adverse events data from phase-IIb trial in Hepatitis-B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 Updated efficacy and safety data from a phase II trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Disease (AASLD-2023)